Media

Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting

Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH

Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies

Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37

Carisma Therapeutics Appoints Sanford Zweifach as Chairman to Board of Directors